Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Interest Expenses (2020 - 2023)

Historic Interest Expenses for Vivos Therapeutics (VVOS) over the last 4 years, with Q4 2023 value amounting to $1.8 million.

  • Vivos Therapeutics' Interest Expenses fell 4000.0% to $1.8 million in Q4 2023 from the same period last year, while for Dec 2023 it was $1.8 million, marking a year-over-year decrease of 4000.0%. This contributed to the annual value of $1.8 million for FY2023, which is 4000.0% down from last year.
  • Latest data reveals that Vivos Therapeutics reported Interest Expenses of $1.8 million as of Q4 2023, which was down 4000.0% from $3.0 million recorded in Q4 2022.
  • In the past 5 years, Vivos Therapeutics' Interest Expenses registered a high of $3.0 million during Q4 2022, and its lowest value of $1000.0 during Q1 2021.
  • Over the past 4 years, Vivos Therapeutics' median Interest Expenses value was $18067.0 (recorded in 2020), while the average stood at $386307.7.
  • As far as peak fluctuations go, Vivos Therapeutics' Interest Expenses plummeted by 9771.29% in 2021, and later soared by 7490000.0% in 2022.
  • Vivos Therapeutics' Interest Expenses (Quarter) stood at $17218.0 in 2020, then tumbled by 76.77% to $4000.0 in 2021, then surged by 74900.0% to $3.0 million in 2022, then plummeted by 40.0% to $1.8 million in 2023.
  • Its Interest Expenses was $1.8 million in Q4 2023, compared to $3.0 million in Q4 2022 and $36000.0 in Q3 2022.